Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7911-7919

  Van Huizen, Isaac ^a   Wu, Guojun ^a   Moussa, Madeleine ^a   Chin, Joseph L ^a   Fenster, Aaron ^a   Lacefield, James C ^a   Sakai, Hideki ^b   Greenberg, Norman M ^c   Xuan, Jim W ^a,d  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Fred Hutchinson Cancer Research Center   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; COMPLEMENTARY DNA; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY PSP94; TUMOR MARKER; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANIMAL CELL; ARTICLE; CANCER HORMONE THERAPY; CONTROLLED STUDY; DISEASE MARKER; DISEASE MODEL; GENETIC ENGINEERING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; THREE DIMENSIONAL IMAGING; TUMOR VOLUME; ULTRASOUND;

ANIMALS; BLOTTING, WESTERN; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; RECOMBINANT PROTEINS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 27744579600     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0953     Document Type: Article

References (36)

1. Jemal A, Murray T, Samuel A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2004;53:5-26.
2. Steiner MS, Gingrich JR. Gene therapy for prostate cancer: where are we now? J Urol 2000;164:1121-36.
3. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:57-60.
4. Stamay TA, Yang N, Hay AR, McNea UE, Freina FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
5. Therasse R, Aubuck S, Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
6. Huss WJ, Maddison LA, Greenberg NM. Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol 2000;11:245-60.
7. Winter SF, Cooper AB, Greenberg NM. Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis 2003;6:204-11.
8. Abate-Shen C, Shen MM. Mouse models of prostate carcinogenesis. Trends Genet 2002;18:S1-5.
9. Greenberg NM, Demayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
10. Masumori N, Thomas TZ, Chaurand P, et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001;61:2239-49.
11. Hara M, Kimura H. Two prostate-specific antigens, γ-seminoprotein and b-microseminoprotein. J Lab Clin Med 1989;113:541-8.
12. Abrahamsson PA, Lilja H, Falkmer S, Wadstrom LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988;12:39-46.
13. Hyakutake H, Sakai H, Yogi Y, et al. β-Microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma. Prostate 1993;22:347-55.
14. Wu D, Guo YZ, Chambers AF, Izawa JI, Chin JL, Xuan JW. Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. J Cell Biochem 1999;76:71-83.
15. Reeves JJ, Xuan JW, Arfanis K, et al. Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem J 2005;385:105-14.
16. Grande M, Carlstrom K, Rozell BL, Stege R, Pousette A. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients. Clin Cancer Res 2000;6:1790-5.
17. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000;6:160-5.
18. Gabril MY, Onita T, Ji PG, et al. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther 2002;9:1589-99.
19. Duan WM, Gabril MY, Moussa M, et al. Knock-in of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate (KIMAP) model demonstrates advantageous features over the transgenic model. Oncogene 2005;24:1510-24.
20. Gabril MY, Duan WM, Wu GJ, et al. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for pre-clinical studies. Mol Ther 2005;11:348-62.
21. Imasato Y, Xuan JW, Sakai H, et al. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer. J Urol 2000;164:1819-24.
22. Xuan JW, Kwong J, Chan FL, et al. cDNA, genomic cloning and gene expression analysis of mouse PSP94 (prostate secretory protein of 94 amino acids). DNA Cell Biol 1999;18:11-26.
23. Thota A, Karajgikar M, Duan WM, et al. Mouse PSP94 expression is prostate tissue-specific as demonstrated by a comparison of multiple antibodies against recombinant proteins. J Cell Biochem 2003;88:999-1011.
24. Wirtzfeld LA, Wu GJ, Bygrave M, et al. Three-dimensional ultrasound micro-imaging for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res 2005;65:6337-45.
25. Hoff J. Methods of blood collection in the mouse. Lab Anim 2000;29:47-53.
26. Imasato Y, Onita T, Moussa M, et al. Rodent PSP94 gene expression is more specific to the dorsolateral prostate and less sensitive to androgen ablation than probasin. Endocrinology 2001;142:2138-46.
27. Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305.
28. Park JH, Walls JE, Galvez JJ, et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol 2002;161:727-35.
29. Lazure C, Villemure M, Gauthier D, Naude RJ, Mbikay M. Characterization of ostrich (Struthio camelus) β-microseminoprotein (MSP): identification of homologous sequences in EST databases and analysis of their evolution during speciation. Protein Sci 2001;10:2207-18.
30. Xuan JW, Wu D, Guo Y, Fraser J, Chin J. Recombinant PSP94 (prostate secretory protein of 94 amino acids) demonstrates similar linear epitope structure as natural PSP94 protein. J Cell Biochem 1996;63:61-74.
31. Xuan JW, Wu D, Guo Y, Huang CL, Wright GL, Jr., Chin JL. Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (II) Epitope mapping by monoclonal antibodies. J Cell Biochem 1997;65:185-97.
32. Xuan JW, Wu D, Guo Y, Garde SV, Baijal-Gupta M, Chin JL. Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (I) immunodominant and immuno-recessive area. J Cell Biochem 1997;65:172-85.
33. Bauman GS, Xuan JW, Chin J, et al. PSP94:Evaluation of prognostic utility in patients treated with radiotherapy for nonmetastatic prostate cancer. Prostate 2000;2:94-101.
34. Kwong J, Xuan JW, Choi HL, Chan PSF, Chan FL. PSP94 (or b-microseminoprotein) is a secretory protein specifically expressed and synthesized in the lateral lobe of the rat prostate. Prostate 2000;42:219-29.
35. Lilja H, Christenssson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with a1-antichymotrypsin. Clin Chem 1991;37:1618-25.
36. Stenman U, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with a1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.